News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,430 Results
Type
Article (42014)
Company Profile (435)
Press Release (665981)
Section
Business (208616)
Career Advice (2020)
Deals (35993)
Drug Delivery (102)
Drug Development (83534)
Employer Resources (170)
FDA (16389)
Job Trends (15069)
News (352570)
Policy (33028)
Tag
Academia (2624)
Alliances (50843)
Alzheimer's disease (1361)
Approvals (16360)
Artificial intelligence (214)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (329)
Breast cancer (231)
Cancer (1760)
Cardiovascular disease (138)
Career advice (1683)
CAR-T (127)
Cell therapy (374)
Clinical research (67088)
Collaboration (698)
Compensation (375)
COVID-19 (2624)
C-suite (167)
Data (1656)
Diabetes (216)
Diagnostics (6342)
Earnings (86678)
Employer resources (147)
Events (114397)
Executive appointments (578)
FDA (17307)
Funding (631)
Gene therapy (266)
GLP-1 (686)
Government (4445)
Healthcare (19102)
Infectious disease (2737)
Inflammatory bowel disease (127)
Interviews (310)
IPO (16740)
Job creations (3698)
Job search strategy (1432)
Layoffs (467)
Legal (7962)
Lung cancer (260)
Manufacturing (244)
Medical device (13414)
Medtech (13419)
Mergers & acquisitions (19620)
Metabolic disorders (580)
Neuroscience (1795)
NextGen: Class of 2025 (6750)
Non-profit (4547)
Northern California (2118)
Obesity (325)
Opinion (213)
Patents (164)
People (58212)
Phase I (21100)
Phase II (29608)
Phase III (21863)
Pipeline (728)
Postmarket research (2600)
Preclinical (8967)
Radiopharmaceuticals (257)
Rare diseases (345)
Real estate (6005)
Regulatory (22387)
Research institute (2407)
Resumes & cover letters (352)
Southern California (1826)
Startups (3755)
United States (18959)
Vaccines (631)
Weight loss (227)
Date
Today (11)
Last 7 days (609)
Last 30 days (2544)
Last 365 days (35447)
2025 (4560)
2024 (36308)
2023 (41025)
2022 (52294)
2021 (56776)
2020 (54928)
2019 (47425)
2018 (35701)
2017 (33034)
2016 (32355)
2015 (38402)
2014 (32194)
2013 (27114)
2012 (29231)
2011 (29873)
2010 (28000)
Location
Africa (734)
Arizona (219)
Asia (38933)
Australia (6481)
California (4885)
Canada (1725)
China (403)
Colorado (221)
Connecticut (242)
Europe (84980)
Florida (692)
Georgia (165)
Illinois (472)
Indiana (262)
Maryland (759)
Massachusetts (3757)
Michigan (200)
Minnesota (340)
New Jersey (1374)
New York (1379)
North Carolina (897)
Northern California (2118)
Ohio (175)
Pennsylvania (1112)
South America (1107)
Southern California (1826)
Texas (717)
Utah (145)
Washington State (485)
708,430 Results for "ascend therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600.
April 30, 2024
·
7 min read
Press Releases
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 7, 2025
·
8 min read
Drug Development
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease.
May 16, 2024
·
6 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
February 3, 2025
·
8 min read
Press Releases
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
January 22, 2025
·
8 min read
Press Releases
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
February 10, 2025
·
6 min read
Drug Development
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Gain Therapeutics, Inc. announces positive results from the single ascending dose (SAD) part of its Phase 1 study.
April 24, 2024
·
7 min read
Drug Development
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.
February 26, 2024
·
7 min read
Press Releases
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
February 19, 2025
·
4 min read
Drug Development
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.
April 19, 2024
·
4 min read
1 of 70,843
Next
